EANS-Adhoc: SYGNIS Pharma AG / SYGNIS Announces Proposed Combination of Business with GENETRIX' subsidiary X-Pol

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Contracts

18.07.2012

Ad hoc-Release according to § 15 WpHG SYGNIS Announces Proposed
Combination of Business with GENETRIX' subsidiary X-Pol

Heidelberg, July18,2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard) and GENETRIX Life Sciences, A.B.,
announced today, that the biotechnology companies have signed a Term
Sheet under which the companies propose to combine GENETRIX Life
Sciences, A.B.'s DNA sequencing subsidiary X-Pol Biotech, S.L.,
(Madrid, Spain) and SYGNIS Pharma AG. Goal is to develop and market
X-Pol Biotech, S.L.'s DNA sequencing technologies and products.
SYGNIS Pharma AG will acquire 100% ownership of X-Pol Biotech, S.L.,
by way of capital increase against contribution in kind and therefore
X-Pol Biotech, S.L., will become a 100% subsidiary of SYGNIS Pharma
AG. According to the business valuation as of today and subject to a
corresponding resolution of the shareholders of SYGNIS Pharma AG, the
existing shareholders of X-Pol Biotech, S.L., will hold 77.5% of all
shares in SYGNIS Pharma AG after the proposed transaction. The
executive and supervisory boards of both companies have voted
unanimously for the proposed key terms of the transaction. The
transaction is subject to an exemption granted by BaFin from the
obligations pursuant to Section 35 of the German Takeover Act
(Wertpapiererwerbs- und Übernahmegesetz), in particular to submit a
mandatory tender offer to the existing shareholders of SYGNIS Pharma
AG in connection with the capital increase of SYGNIS Pharma AG. It is
also dependent on the approval of SYGNIS Pharma AG's shareholders at
the next shareholders' meeting. **** end of ad hoc **** For further
information please contact:

SYGNIS Pharma AG

Peter Willinger
Tel: +49 6221 454 836
Email: {peter.willinger@sygnis.de}

### Disclaimer This publication is intended for information only and
constitutes neither an offer to sell nor an invitation to buy
securities. Some statements included in this press release, relating
neither to proven financial results nor other historical data, should
be viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English